How to Launch a Hair Loss Telehealth Program: The Complete Business Guide

Hair loss is one of the largest and most predictable markets in consumer health. Androgenetic alopecia affects approximately 50 million men and 30 million women in the United States. The medications that treat it work, patients need them continuously to maintain results, and most people experiencing hair loss are highly motivated to act.

For Entrepreneurs and Creators building telehealth brands, hair loss is a compelling program: strong market demand, simple clinical protocols, medications that are not controlled substances, and a subscription model with structural retention built in. For Clinic Owners, adding hair loss programs to an existing practice creates a recurring-revenue stream that complements GLP-1, HRT, TRT, and peptide programs.

This guide covers everything you need to understand before launching: the market opportunity, the medications and how they work, how the business model functions, what you need to get started, the economics, and the regulatory landscape.

The Hair Loss Market Opportunity

The scale of the hair loss market is underappreciated outside the consumer health industry.

Androgenetic alopecia affects about 50% of men by age 50, according to data from the American Academy of Dermatology. Female pattern hair loss affects approximately 30 million American women, with incidence increasing with age. The total addressable market is one of the largest in consumer health.

Despite this scale, most people experiencing hair loss never receive treatment. The barriers are familiar:

• Insurance rarely covers hair loss medications
• Primary care physicians often do not proactively address hair loss
• Stigma, embarrassment, and resignation lead many people to dismiss the condition as inevitable
• Access to a dermatologist or trichologist requires referrals, wait times, and office visits

Telehealth brands have demonstrated decisively that this market converts through digital channels. Hims, Keeps, and Ro built large businesses on oral finasteride by making treatment accessible, discreet, and affordable. The market they opened is far from saturated — and the emergence of compounded topical formulations, oral minoxidil, and dutasteride creates meaningful differentiation opportunities for new entrants.

The most important structural fact about hair loss as a business: the medications only work if you keep taking them. This is not a course of treatment with a defined endpoint. It is indefinite maintenance therapy. Patients who see results are highly motivated to continue because discontinuing reverses those results. That dynamic is the foundation of strong patient retention.

The Medications: What Hair Loss Programs Prescribe

Finasteride (Oral)

Finasteride is a 5-alpha reductase inhibitor that reduces conversion of testosterone to DHT (dihydrotestosterone), the hormone responsible for androgenetic alopecia. It is the most widely prescribed medication for male pattern hair loss.

Oral finasteride 1mg is the standard dose for hair loss. Clinical trials show it halts progression in approximately 83% of men and produces visible regrowth in about 66%, according to studies published in the Journal of the American Academy of Dermatology.

Compounded oral finasteride is available at custom doses and is substantially cheaper than the brand-name Propecia, which makes cash-pay programs viable at price points patients accept.

Sexual side effects (decreased libido, erectile dysfunction) are reported by approximately 2% to 4% of men in clinical trials. Most resolve upon discontinuation. This concern is the primary reason many patients choose topical finasteride over oral.

Finasteride (Topical)

Compounded topical finasteride (typically 0.1% to 0.25% solution) is applied directly to the scalp, where it achieves meaningful local concentrations with substantially lower systemic absorption than oral finasteride. This reduces the systemic DHT suppression that underlies most side effect concerns.

Research published in the Journal of the European Academy of Dermatology and Venereology has shown topical finasteride to be effective for hair loss while producing serum DHT suppression approximately 90% lower than oral finasteride.

Topical finasteride is only available through compounding pharmacies. It cannot be purchased at a retail pharmacy. This makes it a genuine differentiator and a higher-margin product for telehealth brands.

Dutasteride (Oral or Topical)

Dutasteride inhibits both type I and type II 5-alpha reductase (finasteride inhibits only type II), producing greater DHT suppression. It is FDA-approved for benign prostatic hyperplasia and is prescribed off-label for hair loss.

Clinical data suggests dutasteride produces superior hair regrowth compared to finasteride. A randomized trial published in the British Journal of Dermatology found significantly greater hair count increases with dutasteride 0.5mg versus finasteride 1mg.

Compounded topical dutasteride is also available, with a similar rationale to topical finasteride (local efficacy, reduced systemic exposure).

Minoxidil (Topical)

Topical minoxidil (5% solution or foam) is the other cornerstone of hair loss treatment. It works through a different mechanism than finasteride, promoting hair follicle blood supply and extending the anagen (growth) phase. It is FDA-approved for hair loss and available over the counter, but compounded combinations with finasteride are only available through pharmacies.

Oral Minoxidil (Low-Dose)

Low-dose oral minoxidil has emerged as a highly effective and patient-preferred option based on recent research. Doses of 2.5mg for men and 1.25mg for women produce strong hair regrowth results with minimal side effects at these low doses.

A systematic review published in the Journal of the American Academy of Dermatology found low-dose oral minoxidil to be effective and generally well-tolerated. Side effects at low doses (mild body hair increase, fluid retention) are dose-dependent and uncommon at the doses used in hair programs.

Oral minoxidil is compounded at custom doses and is substantially cheaper per month than 5% topical minoxidil foam when comparing daily cost.

Compounded Topical Combinations

The highest-margin, most clinically compelling product in hair loss programs is a compounded topical solution combining finasteride and minoxidil in a single formulation. Patients apply once daily to the scalp and receive the benefits of both medications with minimal systemic exposure and maximum convenience.

This formulation is unavailable through any retail pharmacy or brand-name product. It can only be obtained through a compounding pharmacy with a prescription. Programs that offer it have a genuine product differentiation that drives both conversion and retention.

Spironolactone (for Women)

Spironolactone, an aldosterone antagonist with anti-androgenic properties, is commonly prescribed off-label for female pattern hair loss. It blocks androgen receptors in the scalp, reducing DHT-mediated follicle miniaturization. Doses of 50mg to 200mg are used depending on patient response.

Spironolactone is not used in male patients due to its anti-androgenic effects.

Adjunct Options

Many programs include optional adjuncts that increase average revenue per patient:

• Ketoconazole shampoo (2%): Anti-fungal with documented effect on scalp DHT; compounded or prescription-strength available
• Biotin and hair-specific supplements: Low margin but high attachment rate; patients expect them
• Low-level laser therapy (LLLT) devices: Physical devices sold as add-ons; no prescribing required

Who Your Patients Are

Men With Male Pattern Hair Loss

The largest patient population. Men in their late 20s through 50s experiencing recession at the temples and thinning at the crown. High motivation to act once aware that treatment exists and is accessible. Responds well to before/after creative in digital advertising.

This patient is often embarrassed to raise the topic with a primary care physician and has procrastinated. The telehealth model — discreet, fast, no face-to-face appointment — removes the primary barriers to care.

Men Concerned About Side Effects

A significant subset of potential patients have read about finasteride side effects and want topical options. Topical finasteride programs specifically target this group. Brands that lead with the topical formulation and address the side effect concern directly in their messaging convert this hesitant population that oral-first brands leave behind.

Women With Female Pattern Hair Loss

An underserved patient population, particularly in the 40s and 50s. Female hair thinning often begins around perimenopause and can be distressing. Women are underrepresented in telehealth hair programs because most brands focus on men. A brand that targets women specifically has a less competitive market and a highly motivated patient base.

The Business Model: How Hair Loss Programs Make Money

A hair loss telehealth program is a subscription healthcare business. Revenue comes from monthly program fees paid by patients who remain on ongoing therapy.

The model:

1. Patient acquisition through paid advertising (Meta and Google), organic search, or creator partnerships
2. Intake completion: medical history, hair loss history, contraindication screening, photo submission for visual assessment
3. Eligibility Screen evaluates the Intake before a Provider sees it
4. Provider Review: a licensed Provider reviews the Case and issues a prescription for the appropriate protocol
5. Pharmacy fulfillment: the compounding pharmacy prepares the formulation and ships directly to the patient
6. Monthly subscription: the patient pays a recurring fee covering medication, Provider access, and ongoing monitoring
7. Annual check-in: the Provider reviews response at 6 to 12 months; the prescription is renewed

Why Retention Is Structurally Strong

Hair loss programs have a built-in retention mechanism that most other program types lack: the reversal dynamic. Patients who see results know that stopping treatment reverses those results. This is not theoretical — it is a well-documented clinical fact that patients learn early in treatment.

Programs that communicate the reversal risk clearly and proactively at 3 months and 6 months retain patients at significantly higher rates than programs that do not. The patient who understands they will lose their gains if they cancel is far less likely to cancel on a whim.

Economics: Revenue Model and Patient LTV

Sample Program Economics

Assume a compounded topical combination (finasteride plus minoxidil) program priced at $120 per month.

At a monthly churn rate of 6%, average patient lifetime is approximately 17 months. At $120 per month, average patient lifetime value is approximately $2,040.

If you are acquiring patients at $100 per patient, your payback period is under one month and your return on acquisition spend is over 20x over the patient lifetime.

Tiered Program Economics

Most hair loss brands succeed with a tiered structure:

The upsell from Starter to Core or Complete is the primary revenue lever. Patients on oral-only programs who are educated about topical options upgrade at meaningful rates because the clinical case for combination therapy is strong.

Scale Economics

Hair loss programs have lower average revenue per patient than TRT or HRT programs, but they also have lower clinical cost per patient (no controlled substances, simpler protocols, lower Provider consult frequency) and a large addressable market. Volume is the primary growth lever.

Regulatory Landscape

No Controlled Substances

The absence of controlled substances in standard hair loss protocols is a significant operational advantage over TRT and other hormone programs.

Finasteride, dutasteride, minoxidil, and spironolactone are all non-controlled prescription medications. This means:

• No DEA registration requirements for Providers
• No EPCS (Electronic Prescribing for Controlled Substances) requirements
• Fewer state-specific telehealth prescribing restrictions
• Simpler pharmacy compliance requirements

Hair loss is operationally one of the cleanest programs to run from a regulatory standpoint.

Telehealth Prescribing

Because none of the core hair loss medications are controlled substances, telehealth prescribing is permitted in most states without the additional restrictions that apply to Schedule III medications. Asynchronous telehealth (where the patient completes an Intake and a Provider reviews it without a live video call) is widely permissible for these medications. For a full review of state-by-state telehealth prescribing rules, read our telehealth prescribing guide.

Compounding Pharmacy Rules

Compounded topical finasteride, dutasteride, and minoxidil combinations are prepared under 503A pharmacy rules. These pharmacies must be licensed in the states where your patients are located. Because these formulations are not copies of specific FDA-approved finished drug products (there is no FDA-approved finasteride plus minoxidil topical combination), the compounding legal basis is straightforward. Work with pharmacies that provide potency testing documentation and certificates of analysis.

HIPAA

All platform and pharmacy partners must have Business Associate Agreements in place. Patient intake data and medical records are protected health information. For a full overview, read our HIPAA compliance guide.

Advertising

The FTC regulates before/after claims in hair loss advertising specifically. Before-and-after photos must be representative of typical results, not exceptional cases. Avoid claims of guaranteed regrowth; use “may help,” “clinically shown to reduce hair loss,” or similar qualified language. Review the FTC’s endorsement guides if you plan to use patient testimonials in advertising.

Brand Differentiation: How to Win in a Competitive Market

The hair loss telehealth market has established players (Hims, Keeps, Ro) competing primarily on price for oral finasteride. A new brand that competes on price alone will struggle. The brands that carve out durable market positions do so on one of four strategies:

1. Lead with topical. The side effect concern around oral finasteride is the primary reason men do not start treatment. Brands that lead with “no systemic side effects” via topical formulations convert this hesitant segment that oral-first brands cannot reach.

2. Target women specifically. Female pattern hair loss is underserved by virtually every major telehealth hair brand. A women-first hair brand faces a less competitive market and a patient population with few good alternatives.

3. Bundle comprehensively. Hair loss patients are often interested in broader health optimization. A program that includes compounded topical, oral minoxidil, and a supplement stack at a bundled price increases revenue per patient and reduces the perceived cost of individual components.

4. Build around a community or creator. Hair loss is a topic with strong community dynamics online. Brands built around a creator, a community, or educational content acquire patients at lower cost and retain them at higher rates because the relationship extends beyond the monthly shipment.

Launch Checklist

1. Choose your brand positioning (topical-first, women-focused, comprehensive bundle, or community)
2. Select a white-label clinical platform with Provider Network and pharmacy integration
3. Confirm pharmacy partner specializes in compounded hair loss formulations (topical finasteride/minoxidil combinations)
4. Build patient Intake forms (hair loss history, family history, contraindication screening, photo upload)
5. Set protocol options (oral only, topical only, combination tiers)
6. Create patient onboarding communication (timeline expectations, reversal risk education, side effect guidance)
7. Set pricing and tier structure
8. Configure follow-up workflows (3-month and 6-month check-ins)
9. Build patient acquisition campaigns (Meta and Google for men’s hair loss and/or women’s hair thinning)
10. Establish adjunct product catalog (supplements, LLLT devices, ketoconazole shampoo)

How Karpa Health Helps You Launch

Karpa Health provides the complete infrastructure for launching and scaling a hair loss telehealth program. The Platform includes white-label patient Intake, a 50-state Provider Network, integrated Pharmacy Integration with vetted compounding partners, and the practice management tools needed to run a compliant, scalable program.

You bring the brand and the patients. Karpa Health provides the clinical and operational backbone.

Whether you are building a men’s hair loss brand, a women’s hair health program, or adding hair loss as a program within a broader wellness or hormone optimization practice, the Platform handles the clinical and operational layer.

Explore the entrepreneur program or the clinic owner program to see how Operators across both segments launch on the Platform.

For related context, read our guides on how to launch a telehealth clinic without a medical license, the medical director vs Provider Network decision, and telehealth prescribing compliance.

Start your hair loss program if you are ready to launch with Karpa Health.